BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:NT-112 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of NT-112\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06218914-2644@assetmemo.bio
DTSTAMP:20261121T005417Z
DTSTART;VALUE=DATE:20270830
DTEND;VALUE=DATE:20270831
SUMMARY:NT-112: Phase 1 readout est. (NCT06218914)
DESCRIPTION:NT-112\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: Phase 1 
 Study to Investigate TCRTs KRAS Mutation in Unresectable\, Advanced\, and/
 or Metastatic Solid Tumors\nEstimated primary completion: 30 August 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/nt-112#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06218914
URL:https://assetmemo.bio/drug/nt-112#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
